Profile data is unavailable for this security.
About the company
Kintara Therapeutics, Inc. is a biopharmaceutical company focused on the development of new solid tumor cancer therapies. The Company's lead program is REM-001 Therapy for cutaneous metastatic breast cancer (CMBC). REM-001, is a late-stage photodynamic therapy (PDT). PDT is a treatment that uses light sensitive compounds, or photosensitizers, that, when exposed to specific wavelengths of light, act as a catalyst to produce a form of reactive oxygen that induces local tumor cell death. It has a proprietary, late-stage photodynamic therapy platform. REM-001 Therapy consists of the laser light source, the light delivery device, and the REM-001 drug product. Its product candidate, VAL-083, is a DNA-targeting agent intended to treat drug-resistant solid tumors, such as glioblastoma (GBM) and potentially other smaller tumors, from the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study. VAL-083 is also used for various other indications.
- Revenue in USD (TTM)0.00
- Net income in USD-9.51m
- Incorporated2009
- Employees2.00
- LocationKintara Therapeutics Inc9920 Pacific Heights BlvdSuite 150, Suite 200SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 350-4364
- Fax+1 (604) 202-1384
- Websitehttps://www.kintara.com/
Mergers & acquisitions
Acquired company | KTRA:NAQ since announced | Transaction value |
---|---|---|
TuHURA Biosciences Inc | 74.00% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Viracta Therapeutics Inc | 0.00 | -45.34m | 8.82m | 40.00 | -- | -- | -- | -- | -1.16 | -1.16 | 0.00 | 0.0678 | 0.00 | -- | -- | 0.00 | -83.82 | -86.35 | -140.98 | -106.38 | -- | -- | -- | -11,853.94 | -- | -59.78 | 0.8753 | -- | -- | -- | -3.78 | -- | -- | -- |
Molecular Templates Inc | 25.47m | -15.63m | 8.89m | 62.00 | -- | 1.25 | -- | 0.349 | -2.70 | -2.70 | 4.24 | 1.08 | 0.8189 | -- | 47.65 | 410,806.40 | -50.24 | -51.78 | -113.26 | -73.14 | -- | -- | -61.35 | -228.33 | -- | -- | 0.00 | -- | 190.10 | 33.96 | 91.24 | -- | -48.87 | -- |
BioCardia Inc | 428.00k | -8.56m | 8.89m | 16.00 | -- | -- | -- | 20.78 | -5.40 | -5.40 | 0.2636 | -0.9233 | 0.0923 | -- | 6.85 | 26,750.00 | -184.48 | -107.34 | -1,075.25 | -154.17 | -- | -- | -1,999.77 | -1,779.24 | -- | -- | -- | -- | -64.72 | -5.26 | 2.82 | -- | -28.89 | -- |
Inhibikase Therapeutics Inc | 79.57k | -18.38m | 8.96m | 8.00 | -- | 1.70 | -- | 112.57 | -2.93 | -2.93 | 0.0126 | 0.7063 | 0.0051 | -- | -- | 9,946.25 | -117.93 | -66.49 | -148.63 | -85.55 | -- | -- | -23,102.16 | -1,139.14 | -- | -- | 0.00 | -- | 111.03 | -42.21 | -5.40 | -- | -- | -- |
Portage Biotech Inc | 0.00 | -71.08m | 9.15m | 7.00 | -- | 3.64 | -- | -- | -68.81 | -68.81 | 0.00 | 2.39 | 0.00 | -- | -- | 0.00 | -137.29 | -30.53 | -143.21 | -40.02 | -- | -- | -- | -- | -- | -- | 0.02 | -- | -- | -- | 27.98 | -- | -- | -- |
Kintara Therapeutics Inc | 0.00 | -9.51m | 9.63m | 2.00 | -- | -- | -- | -- | -4.08 | -4.08 | 0.00 | 0.1071 | 0.00 | -- | -- | 0.00 | -131.55 | -220.94 | -185.60 | -329.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 40.24 | -- | 78.93 | -- |
Plus Therapeutics Inc (USA) | 5.51m | -13.23m | 9.67m | 20.00 | -- | -- | -- | 1.76 | -3.05 | -3.05 | 1.19 | -1.34 | 0.4336 | -- | -- | 275,450.00 | -104.14 | -59.18 | -- | -133.04 | -- | -- | -240.15 | -470.45 | -- | -4.17 | -- | -- | 2,093.30 | -5.89 | 34.32 | -- | 3.77 | -- |
Kazia Therapeutics Ltd (ADR) | 15.35k | -13.93m | 9.67m | 12.00 | -- | 0.9028 | -- | 630.04 | -0.8448 | -0.8448 | 0.0008 | 0.3597 | 0.0007 | -- | 73.97 | -- | -63.98 | -46.35 | -82.39 | -54.75 | -- | -- | -90,714.45 | -497.17 | -- | -- | 0.1297 | -- | 979.43 | -28.31 | 18.19 | -- | -- | -- |
Oncotelic Therapeutics Inc | 70.00k | -1.24m | 9.75m | 22.00 | -- | 0.8041 | -- | 139.29 | -0.0031 | -0.0031 | 0.0002 | 0.0299 | 0.0023 | -- | 3.69 | 3,181.82 | -5.02 | -25.03 | -11.26 | -48.76 | -- | -- | -2,147.66 | -1,692.93 | -- | -0.5167 | 0.5228 | -- | -- | -- | -255.12 | -- | -- | -- |
Check Cap Ltd | 0.00 | -17.57m | 9.89m | 85.00 | -- | 0.4174 | -- | -- | -3.00 | -3.00 | 0.00 | 4.05 | 0.00 | -- | -- | -- | -49.87 | -54.23 | -53.46 | -60.24 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 8.06 | -- | -2.46 | -- |
Jaguar Health Inc | 10.19m | -35.67m | 9.89m | 49.00 | -- | 0.4954 | -- | 0.9709 | -41.34 | -41.34 | 6.62 | 2.48 | 0.1793 | 0.231 | 7.56 | 207,857.10 | -63.73 | -95.29 | -110.34 | -163.54 | 79.79 | 67.28 | -355.51 | -522.28 | 1.60 | -3.45 | 0.6333 | -- | -18.36 | 17.19 | 12.97 | -- | -- | -- |
Virax Biolabs Group Ltd | 156.42k | -6.73m | 9.94m | 17.00 | -- | 1.17 | -- | 63.55 | -3.35 | -3.35 | 0.078 | 2.09 | 0.0205 | 3.51 | -- | 9,201.18 | -88.11 | -- | -91.88 | -- | 32.34 | -- | -4,308.35 | -- | 25.58 | -227.16 | 0.0418 | -- | 1,727.34 | -- | -23.38 | -- | -- | -- |
Avalo Therapeutics Inc | 807.00k | -36.22m | 10.05m | 19.00 | -- | -- | -- | 12.46 | -63.82 | -63.82 | 0.3347 | -2.08 | 0.0122 | -- | 20.96 | 42,473.68 | -54.66 | -99.64 | -529.15 | -154.42 | 64.19 | 84.69 | -4,488.60 | -613.58 | -- | -- | -- | -- | -89.34 | -22.83 | 24.28 | -- | -22.48 | -- |
Nymox Pharmaceutical Corp | 0.00 | -8.84m | 10.29m | 3.00 | -- | -- | -- | -- | -0.0966 | -0.0966 | 0.00 | -0.0339 | 0.00 | -- | -- | -- | -785.44 | -306.39 | -- | -749.37 | -- | -- | -- | -43,683.47 | -- | -157.57 | -- | -- | -- | -- | -34.49 | -- | -39.16 | -- |
Forte Biosciences Inc | 0.00 | -35.76m | 10.34m | 11.00 | -- | 0.6085 | -- | -- | -22.03 | -22.03 | 0.00 | 11.64 | 0.00 | -- | -- | 0.00 | -124.89 | -72.06 | -170.91 | -82.27 | -- | -- | -- | -491,850.00 | -- | -- | 0.00 | -- | -- | -- | -126.79 | -- | -46.29 | -- |
Enzon Pharmaceuticals Inc | 26.00k | 314.00k | 10.45m | 0.00 | 33.29 | 3.44 | -- | 401.90 | 0.0042 | 0.0042 | 0.0004 | 0.6277 | 0.0006 | -- | -- | -- | 3.39 | -0.8654 | 3.42 | -0.8851 | -- | -- | 6,111.54 | -159.43 | -- | -- | 0.00 | -- | -100.00 | -- | 106.71 | -55.86 | -- | -- |
Holder | Shares | % Held |
---|---|---|
Geode Capital Management LLCas of 30 Jun 2024 | 343.91k | 0.62% |
G1 Execution Services LLCas of 30 Jun 2024 | 109.26k | 0.20% |
UBS Securities LLCas of 30 Jun 2024 | 75.82k | 0.14% |
XTX Markets LLCas of 30 Jun 2024 | 74.12k | 0.13% |
Jane Street Capital LLCas of 30 Jun 2024 | 47.87k | 0.09% |
Level Four Advisory Services LLCas of 30 Jun 2024 | 44.64k | 0.08% |
Baader Bank AG (Investment Management)as of 30 Jun 2024 | 42.67k | 0.08% |
Clear Creek Financial Management LLCas of 30 Jun 2024 | 27.50k | 0.05% |
Integrated Wealth Concepts LLCas of 30 Jun 2024 | 22.00k | 0.04% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 12.46k | 0.02% |